retatrutide developer eli lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application Lilly's new diabetes drug doubled

[3] [4] Based on Phase 2 clinical trial data published in the New England Journal of Medicine in 2023 covering both obesity and type 2 diabetes populations retatrutide was administered as a once-weekly subcutaneous injection within those trial protocols

The GLP-1 patches, on the other hand, do not contain any GLP-1 drug

For UK availability, visit the Retatrutide UK page

Understanding the causes and implementing targeted management approaches can help you maintain your treatment goals whilst minimising discomfort

The most common adverse effects are gastrointestinal in nature, including nausea, vomiting, diarrhoea, constipation, and abdominal discomfort

Several mechanisms explain why semaglutide may cause headaches